Several drug-resistant variants have been developed by growing the parental MEL cells in presence of colchicine, adriamycin and vincristine respectively with stepwise increasing concentration. Both the colchicine-resi...Several drug-resistant variants have been developed by growing the parental MEL cells in presence of colchicine, adriamycin and vincristine respectively with stepwise increasing concentration. Both the colchicine-resistant Sc9(ColO) and vincristine-resis-tant Sc9(VCR5) cells displayed an accelerated HMBA-induced commitment to terminal cell differentiation, whereas the adriamycin-resistant SC9 (A 120) showed no acceleration but rather a substantial delay in HMBA-induced differentiation. The studies provide more clues as well as experimental models for further study on the mechanism of induced differentiation of MEL cells.展开更多
After injecting VP16, MEL cells and MEL-TF19 cells into the body of mice, with those injected with the same dose of saline as the control group, we observed the mice for their blood pictures, histological changes of t...After injecting VP16, MEL cells and MEL-TF19 cells into the body of mice, with those injected with the same dose of saline as the control group, we observed the mice for their blood pictures, histological changes of the liver and spleen, and the hemorhelogical indexes within 4 weeks. The results indicated that after injecting MEL cells, the mice entered into a pathological status similar to erythroleukemia, which had the following exhibitions: the tissue structures of the liver and spleen were damaged, a mass of proerythroblasts, basophil erythroblasts and polychromatophilic erythroblasts could be observed on the smears of the bone marrow and spleen, and the deformability and orientation ability of erythrocytes were both depressed. The pathogenicity of MEL-TF19 cells carrying TFAR19 gene was obviously lower than that of MEL cells, and the MEL-TF19 cells even lost their faintish pathogenicity under the apop-tosis-inducing effect of the chemotherapeutic reagent. The outcome from the animal experiments suggests that the TFAR19 gene suppresses the pathogenicity of MEL cells to the mice, and the effect may be better exerted with the synergy of the chemotherapeutic reagent.展开更多
文摘Several drug-resistant variants have been developed by growing the parental MEL cells in presence of colchicine, adriamycin and vincristine respectively with stepwise increasing concentration. Both the colchicine-resistant Sc9(ColO) and vincristine-resis-tant Sc9(VCR5) cells displayed an accelerated HMBA-induced commitment to terminal cell differentiation, whereas the adriamycin-resistant SC9 (A 120) showed no acceleration but rather a substantial delay in HMBA-induced differentiation. The studies provide more clues as well as experimental models for further study on the mechanism of induced differentiation of MEL cells.
基金the National Natural Science Foundation of China (Grant Nos. 30270355 & 10572007)
文摘After injecting VP16, MEL cells and MEL-TF19 cells into the body of mice, with those injected with the same dose of saline as the control group, we observed the mice for their blood pictures, histological changes of the liver and spleen, and the hemorhelogical indexes within 4 weeks. The results indicated that after injecting MEL cells, the mice entered into a pathological status similar to erythroleukemia, which had the following exhibitions: the tissue structures of the liver and spleen were damaged, a mass of proerythroblasts, basophil erythroblasts and polychromatophilic erythroblasts could be observed on the smears of the bone marrow and spleen, and the deformability and orientation ability of erythrocytes were both depressed. The pathogenicity of MEL-TF19 cells carrying TFAR19 gene was obviously lower than that of MEL cells, and the MEL-TF19 cells even lost their faintish pathogenicity under the apop-tosis-inducing effect of the chemotherapeutic reagent. The outcome from the animal experiments suggests that the TFAR19 gene suppresses the pathogenicity of MEL cells to the mice, and the effect may be better exerted with the synergy of the chemotherapeutic reagent.
